UVE vs. RIGL
UVE (Universal Insurance Holdings, Inc.) and RIGL (Rigel Pharmaceuticals, Inc.) are both stocks. UVE operates in Insurance - Property & Casualty (Financial Services), while RIGL operates in Biotechnology (Healthcare). Over the past 10 years, UVE returned 11.60%/yr vs 3.86%/yr for RIGL. Their 0.17 correlation means their historical movements had little consistent relationship.
Performance
UVE vs. RIGL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, UVE achieves a 30.90% return, which is significantly higher than RIGL's -14.06% return. Over the past 10 years, UVE has outperformed RIGL with an annualized return of 11.60%, while RIGL has yielded a comparatively lower 3.86% annualized return.
UVE
- 1D
- -0.27%
- 1M
- 2.00%
- 6M
- 45.30%
- YTD
- 30.90%
- 1Y
- 94.12%
- 3Y*
- 46.91%
- 5Y*
- 30.64%
- 10Y*
- 11.60%
- ALL TIME*
- 42.23%
RIGL
- 1D
- -3.28%
- 1M
- -4.93%
- 6M
- 5.59%
- YTD
- -14.06%
- 1Y
- 68.01%
- 3Y*
- 40.40%
- 5Y*
- -1.65%
- 10Y*
- 3.86%
- ALL TIME*
- -10.60%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $11.43M | $14.01M | $13.32M | |
| $9.93M | $10.08M | $8.48M |
UVE vs. RIGL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
UVE Universal Insurance Holdings, Inc. | 30.90% | 65.32% | 36.80% | 58.14% | -33.52% | 18.39% | -43.50% | -24.24% | 41.44% | -0.88% |
RIGL Rigel Pharmaceuticals, Inc. | -14.06% | 154.64% | 16.00% | -3.33% | -43.40% | -24.29% | 63.55% | -6.96% | -40.72% | 63.03% |
Correlation
The correlation between UVE and RIGL is 0.09, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.09 |
Correlation (3Y) Balances recent behavior with more history. | 0.21 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.16 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.17 |
Correlation (All Time) Calculated using the full available price history since Jun 6, 2003 | 0.17 |
The correlation between UVE and RIGL shifts across timeframes, from 0.09 (1 year) to 0.21 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
UVE:
$1.22B
RIGL:
$681.06M
UVE:
$10.18
RIGL:
$18.94
UVE:
4.29
RIGL:
1.94
UVE:
0.04
RIGL:
0.00
UVE:
0.58
RIGL:
2.36
UVE:
$1.63B
RIGL:
$299.77M
UVE:
$268.35M
RIGL:
$279.95M
UVE:
$307.81M
RIGL:
$125.80M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
UVE vs. RIGL — Risk / Return Rank
UVE
RIGL
UVE vs. RIGL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Universal Insurance Holdings, Inc. (UVE) and Rigel Pharmaceuticals, Inc. (RIGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| UVE | RIGL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.27 | ||
| Sortino ratioReturn per unit of downside risk | +1.16 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.25 | +0.15 |
| Calmar ratioReturn relative to maximum drawdown | 5.11 | 1.50 | +3.61 |
| Martin ratioReturn relative to average drawdown | 13.48 | 2.51 | +10.97 |
Loading charts...
Drawdowns
UVE vs. RIGL - Drawdown Comparison
The maximum UVE drawdown since its inception was -80.46%, smaller than the maximum RIGL drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for UVE and RIGL.
Loading charts...
Drawdown Indicators
| UVE | RIGL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -80.46% | -99.37% | +18.91% |
Max Drawdown (1Y)Largest decline over 1 year | -17.74% | -50.08% | +32.34% |
Max Drawdown (3Y)Largest decline over 3 years | -25.75% | -50.76% | +25.01% |
Max Drawdown (5Y)Largest decline over 5 years | -54.23% | -83.85% | +29.62% |
Max Drawdown (10Y)Largest decline over 10 years | -79.58% | -86.40% | +6.82% |
Current DrawdownCurrent decline from peak | -2.56% | -96.55% | +93.99% |
Average DrawdownAverage peak-to-trough decline | -36.11% | -90.93% | +54.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.71% | 29.86% | -23.15% |
Volatility
UVE vs. RIGL - Volatility Comparison
Universal Insurance Holdings, Inc. (UVE) has a higher volatility of 16.70% compared to Rigel Pharmaceuticals, Inc. (RIGL) at 11.97%. This indicates that UVE's price experiences larger fluctuations and is considered to be riskier than RIGL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| UVE | RIGL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.70% | 11.97% | +4.73% |
Volatility (6M)Calculated over the trailing 6-month period | 29.01% | 34.77% | -5.76% |
Volatility (1Y)Calculated over the trailing 1-year period | 38.72% | 70.02% | -31.30% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 42.78% | 85.52% | -42.74% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 41.57% | 82.76% | -41.19% |
Dividends
UVE vs. RIGL - Dividend Comparison
UVE's dividend yield for the trailing twelve months is around 2.13%, while RIGL has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RIGL Rigel Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
UVE Universal Insurance Holdings, Inc. | 1.76% | 2.28% | 3.66% | 4.82% | 7.27% | 4.53% | 5.10% | 2.75% | 1.93% | 2.52% | 2.43% | 2.72% |
Financials
UVE vs. RIGL - Financials Comparison
This section allows you to compare key financial metrics between Universal Insurance Holdings, Inc. and Rigel Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
UVE vs. RIGL - Profitability Comparison
UVE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Universal Insurance Holdings, Inc. reported a gross profit of -163.41M and revenue of 429.09M. Therefore, the gross margin over that period was -38.1%.
RIGL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.
UVE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Universal Insurance Holdings, Inc. reported an operating income of 83.21M and revenue of 429.09M, resulting in an operating margin of 19.4%.
RIGL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.
UVE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Universal Insurance Holdings, Inc. reported a net income of 59.19M and revenue of 429.09M, resulting in a net margin of 13.8%.
RIGL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.
Frequently Asked Questions
UVE and RIGL have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
UVE has higher volatility (16.70%) compared to RIGL (11.97%). In terms of maximum drawdown, UVE dropped -80.46% vs RIGL's -99.37%.
UVE currently has the higher Sharpe Ratio (2.34 vs 1.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for UVE and RIGL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer